Edition:
United States

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

26.72USD
29 Jul 2016
Change (% chg)

$0.13 (+0.49%)
Prev Close
$26.59
Open
$26.68
Day's High
$26.81
Day's Low
$26.66
Volume
11,012
Avg. Vol
313,094
52-wk High
$70.40
52-wk Low
$17.94

Latest Key Developments (Source: Significant Developments)

Amag Pharma- FDA provides manufacturing update on Makena
Friday, 22 Jul 2016 06:04am EDT 

Amag Pharmaceuticals Inc : Notified by FDA that prior approval supplement for coldstream labs approved for manufacture of preservative-free formulation of Makena .Approval provides company with an alternative manufacturer for single-dose formulation of Makena.  Full Article

AMAG Pharmaceuticals Inc gives FY 2016 guidance
Tuesday, 3 May 2016 07:00am EDT 

AMAG Pharmaceuticals Inc:Expects FY 2016 non-GAAP total product revenue of $520 - $570 million.Expects FY 2016 non-GAAP adjusted EBITDA of $255- $285 million.Expects FY 2016 non-GAAP net income of $195- $225 million.  Full Article

AMAG Pharmaceuticals Inc gives FY 2016 guidance
Wednesday, 17 Feb 2016 07:00am EST 

AMAG Pharmaceuticals Inc:Expects FY 2016 total revenue in the range of $520-$570 mln.Expects FY 2016 non-GAAP adjusted EBITDA in the range of $255- $285 mln.  Full Article

AMAG Pharmaceuticals Inc gives FY 2016 guidance
Monday, 11 Jan 2016 08:00am EST 

AMAG Pharmaceuticals Inc:Expects FY 2016 total revenue of $520 mln - $570 mln.Expects FY 2016 non-GAAP adjusted EBITDA of $255 mln - $285 mln.Expects FY 2016 non-GAAP cash earnings of $195 mln - $225 mln.  Full Article

AMAG Pharmaceuticals announces $60 million share repurchase program
Wednesday, 6 Jan 2016 08:00am EST 

AMAG Pharmaceuticals:Board of Directors has approved a share repurchase program under which AMAG may purchase up to $60 million of its common stock.  Full Article

AMAG Pharmaceuticals Inc - FDA again rejects single-dose use of AMAG's Makena - Reuters
Wednesday, 18 Nov 2015 06:45pm EST 

AMAG Pharmaceuticals Inc:AMAG Pharmaceuticals Inc said the U.S. Food and Drug Administration rejected a single dose of its hormone injection used to reduce the risk of premature birth, the agency's second rebuff in six months - RTRS.The company's shares fell 8 percent to $26.13 in after-hours trading on Wednesday - RTRS.FDA had rejected the company's application in May and requested more information on its manufacturing procedures - RTRS.The hormone injection, Makena, is currently approved and marketed in multi-dose and remains unaffected by FDA's Wednesday decision - RTRS.The multiple dose is approved to lower the risk of premature birth in pregnant women who has had one premature baby - RTRS.  Full Article

AMAG Pharmaceuticals Inc - UK cost watchdog turns down Amgen's new cholesterol drug - Reuters
Wednesday, 18 Nov 2015 06:20am EST 

AMAG Pharmaceuticals Inc:Amgen's new injectable cholesterol drug Repatha has been turned down for use on Britain's state health service, underscoring a worldwide debate about the value of such pricey medicines - RTRS.Repatha belongs to a potent new class of drugs known as PCSK9 inhibitors that are extremely effective at lowering "bad" LDL cholesterol - RTRS.But the National Institute for Health and Care Excellence (NICE) cost watchdog said on Wednesday the question as to whether this would reduce heart attacks and strokes remained unanswered, given a lack of long-term clinical outcomes studies - RTRS.NICE, which decides if treatments should be paid for on the National Health Service (NHS), also said in its draft guidance that analyses presented by Amgen had limitations that "called into question the reliability of the cost-effectiveness results" - RTRS.Amgen said it was disappointed by the decision, since the evidence "strongly indicates that high cholesterol is linked to heart attacks and strokes", and it aimed to provide more data and analyses to demonstrate the cost-effectiveness of Repatha - RTRS.  Full Article

AMAG Pharmaceuticals Inc updates FY 2015 guidance
Tuesday, 3 Nov 2015 07:30am EST 

AMAG Pharmaceuticals Inc:Updates FY 2015 guidance to include revenue from CBR and reflect the business performance for the first nine months and the outlook for the remainder of 2015.Expects FY 2015 total revenue of $425 - $450 mln (prior guidance $395 - $430 mln).Expects FY 2015 adjusted EBITDA of $210 - $225 mln (prior guidance $210 - $225 mln).Expects FY 2015 cash earnings of $165 - $180 mln (prior guidance $180 - $195 mln).  Full Article

AMAG Pharmaceuticals Inc completes acquisition of CBR Acquisition Holdings Corp
Monday, 17 Aug 2015 04:17pm EDT 

AMAG Pharmaceuticals Inc:Completes its previously announced acquisition of CBR Acquisition Holdings Corp., through its wholly-owned subsidiary, Cbr Systems, Inc.  Full Article

AMAG Pharmaceuticals announces pricing of private offering of $500 million of senior notes due 2023
Wednesday, 12 Aug 2015 04:01pm EDT 

AMAG Pharmaceuticals Inc:Announces pricing of private offering of $500 million of senior notes due 2023.Priced its offering of $500 million aggregate principal amount of 7.875% senior notes due 2023.Says notes were priced at an issue price of 100% of their face amount.  Full Article

BRIEF-Amag Pharmaceuticals says Point72's Steven Cohen reported 5 pct passive stake co - SEC filing

* Point72 Asset Management's Steven Cohen reports 5 pct passive stake in Amag Pharmaceuticals as of July 25 - SEC Filing Source: (http://bit.ly/2acSHS4 ) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)